Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188592 | 0.71 | — | — | |
| SCHEMBL28100971 | 0.70 | — | — | |
| SCHEMBL2058439 | 0.69 | — | — | |
| SCHEMBL3926728 | 0.68 | MAPT (0.39) | MAPT | |
| SCHEMBL7012276 | 0.68 | — | — | |
| SCHEMBL7193119 | 0.67 | — | — | |
| SCHEMBL12188761 | 0.67 | MAPT (0.43) | MAPT | |
| SCHEMBL4782051 | 0.67 | MAPT (0.43) | MAPT | |
| SCHEMBL4635289 | 0.67 | — | — | |
| SCHEMBL2020312 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093409-B2 | Method for producing cyclic unsaturated compound | NIPPON SHOKUBAI CO., LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20090299009-A1 | METHOD FOR PRODUCING CYCLIC UNSATURATED COMPOUND | NIPPON SHOKUBAI CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2061778-A1 | METHOD FOR PRODUCING CYCLIC UNSATURATED COMPOUND | Nippon Shokubai Co., Ltd. (JP) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008023823-A1 | METHOD FOR PRODUCING CYCLIC UNSATURATED COMPOUND | NIPPON SHOKUBAI CO., LTD. (JP) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299009-A1 | METHOD FOR PRODUCING CYCLIC UNSATURATED COMPOUND | FASN, SQLE, ALOX5 | MAPT 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.